CFM
COLL icon

Catalyst Funds Management’s Collegium Pharmaceutical COLL Stock Holding History

Catalyst Funds Management’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-800
Closed -$30.9K – 531
2024
Q3 		$30.9K Buy
800
+600
+300% +$21.4K 0.01% 972
2024
Q2 		$6.44K Sell
200
-3,100
-94% -$107K ﹤0.01% 1014
2024
Q1 		$128K Buy
+3,300
New +$115K 0.04% 349

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Catalyst Funds Management's COLL Position: Q4 2024 in Review

Catalyst Funds Management sold out of Collegium Pharmaceutical (COLL) in Q4 2024, closing a stake of 800 shares — an estimated $30.9K sold.

Catalyst Funds Management first reported a position in COLL in Q1 2024 and held it in 3 quarters. The position peaked at $128K in Q1 2024. 238 funds tracked by Wall St. Rank hold COLL as of Q4 2024.

  • Catalyst Funds Management reported no remaining Collegium Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 800 Collegium Pharmaceutical shares in Q4 2024, an estimated $30.9K.
  • Catalyst Funds Management first reported a position in Collegium Pharmaceutical in Q1 2024 and held it in 3 quarters.
  • Catalyst Funds Management's Collegium Pharmaceutical position peaked at $128K in Q1 2024.
  • 238 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.